Two National Institute of Health (NIH) grants totaling over $1.3 million will enable research into antibody-mediated drug delivery technology for the treatment of cancer and autoimmune disorders. L. Nathan Tumey, assistant professor of pharmaceutical sciences, is the Principal Investigator on both grants — $1.2 million from the National Institute of General Medical Sciences and $150,000 from the National Institute of Allergy and Infectious Diseases.
William L. “Bill” Greene, PharmD, chief pharmaceutical officer, to receive the 2021 Shelby Rhinehart Public Service Lifetime Achievement Award.
Researchers at the Finnish Center for Artificial Intelligence have developed a machine learning-based method that produces synthetic data, making it possible for researchers to share even sensitive data with one other without privacy concerns.
Giving a new spin to conventional chemical synthesis, a team of researchers from the National University of Singapore (NUS) has developed a way to automate the production of small molecules suitable for pharmaceutical use. The method can potentially be used for molecules that are typically produced via manual processes, thereby reducing the manpower required.
To make drugs and their development safer for children, researchers at Aalto University and the pharmaceutical company Novartis have developed a method to help determine safe drug doses more quickly. The new organ maturation model is more data-driven and consequently less prone to bias.
ASME’s VisualizeMED: Modeling and Simulation in Medicine will take place on April 14-15, 2021. This two-day virtual event is enabling the transformation of modeling and simulation in medicine by bringing together industry experts of technology and masters of technique who are effectively implementing it with the goal to increase the application and adoption on a global scale.
A team of researchers from Finland and Germany have found a way to study the endonuclease-driven digestion of drug-loaded DNA nanostructures in real time. As the team investigated the binding of anti-cancer drug doxorubicin (Dox) to the DNA structures in great detail, they discovered that the majority of previous studies have vastly overestimated the Dox loading capacity of DNA origami.
The Center for Computational Imaging and Personalized Diagnostics (CCIPD) at Case Western Reserve University and Boehringer Ingelheim, one of the world’s largest pharmaceutical companies will leverage the power of CCIPD’s image computing AI solutions to identify patterns and links between cellular response and underlying molecular drivers, with the goal of advancing therapeutics for diseases with no satisfactory treatment option.
Anyone with a smartphone can download the app ViDok, which lets users pick from a library of molecules that might bind to key proteins on the SARS-CoV-2 virus, which causes COVID-19, and then can tweak the molecules to try to find a better fit.
One of the fastest-growing pharmaceuticals companies in the country, headquartered in Lexington County, today announced several major expansion and investment projects.
Millions of people around the world over the age of 70 are taking at least one medication every day that is causing them more harm than good, leading to falls, confusion, hospitalisation and even death.
Access to healthcare has been at the forefront of social and political debate for decades. Reliable and equitable access to provider prescribed medications is tantamount to the delivery of appropriate healthcare, and the lifecycle of medication manufacturing, distribution, pricing and procurement has been shrouded in an incomprehensible array of transactions and involved stakeholders. Among the middlemen interspersed between pharmaceutical manufacturers and patients are pharmacy benefit managers (PBM). Initially tasked with administering drug plans for health insurers,1 the role of PBMs has expanded over time. They currently function in a lightly regulated area,2,3 with few requirements for business transparency. Three PBMs, CVS Caremark, Optum RX, and Express Scripts, control distribution of nearly ¾ of the medications in the United States.
Lawrence Livermore National Laboratory scientists are contributing to the global fight against COVID-19 by combining artificial intelligence/machine learning, bioinformatics and supercomputing to help discover candidates for new antibodies and pharmaceutical drugs to combat the disease.
For many years, Pinar Keskinocak has studied how pandemics spread through the nation, how they overburden health care systems, and how they diminish the supply of medications, thus worsening the pandemic. All this also spins off additional medical crises. She…
Panos Kouvelis 314-935-4604 [email protected] Please read: https://source.wustl.edu/2020/02/washu-expert-coronavirus-far-greater-threat-than-sars-to-global-supply-chain/ Please watch: https://youtu.be/ATzgs67Dnx8 Original post https://alertarticles.info